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E-mail addresses: michele.caraglia@alice.Zoledronic acid (ZOL) is an aminobisphosphonate able to inhibit the prenylation of intracel-
lular proteins through the inhibition of farnesylpyrophosphate synthase. Prenylation is
essential for the maintenance of the activation of components of signal transduction path-
ways regulating apoptosis and proliferation such as Ras and Ras-related proteins. ZOL has
demonstrated a direct anti-tumour effect in vitro and in preclinical models, and its ability
in preventing skeletal-related events is proven in patients with bone metastases from dif-
ferent origins. Clinical evidence on its direct anti-proliferative effects is emerging. We
describe several strategies in order to improve the anti-tumour activity of ZOL. In detail,
we illustrate new combinations between ZOL and cytotoxic drugs or other biological agents
such as the farnesyltransferase inhibitor tipifarnib focusing on the sequence of administra-
tion of these drugs. Moreover, the efforts to find new molecular targets of ZOL through the
use of technological platforms such as DNA microarrays are described.
 2008 Elsevier Ltd. All rights reserved.1. Introduction acid (ZOL), have a unique mechanism of action, and are activeBisphosphonates (BPs), synthetic analogues of the endoge-
nous pyrophosphate molecule, inhibit osteoclast-mediated
bone destruction selectively adsorbing to mineral surfaces
on bone that are surrounded by osteoclasts. BPs are then re-
leased from the bone surface, where they are internalised
by and disrupt the bone-resorbing action of osteoclasts.1,2
BPs significantly reduce the incidence of skeletal-related
events (SRE), and have analgesic effects on bone pain.3 Newer
nitrogen-containing bisphosphonates, such as zoledronicer Ltd. All rights reserved
nt of Biochemistry and B
815665863.
it, michele.caraglia@uninat micromolar concentrations compared with the first-gener-
ation compounds.4
BPs are stable synthetic analogues of pyrophosphate. Un-
like pyrophosphate which has a P–O–P central structure, BPs
have a carbon atom bridging the two phosphate groups in-
stead, giving a fundamental P–C–P backbone structure, that
is essential for their biological activity.
Studies of the relationships between BPs structure and
anti-resorptive potency suggested that the ability of bisphos-
phonates to inhibit bone resorption depends on two separate.
iophysics, II University of Naples, Via Costantinopoli, 16 80138
a2.it (M. Caraglia).
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nate groups, together with a hydroxyl group at the R1 position
often called the ‘hook’, mainly influence chemical properties
and pharmacokinetics imparting high affinity for bone min-
eral and allowing rapid and efficient targeting of bisphospho-
nates to bone mineral surfaces. Once localised within the
bone, the structure and three-dimensional conformation of
the R2 side chain (as well as the phosphonate groups in the
molecule) determine the biological activity of the molecule
and influence the ability of the drugs to interact with specific
molecular targets.6
Zoledronic acid marketed by Novartis under the trade
names Zometa7 is the most potent commercially available
nitrogen-containing BP to date, characterised by an imidazole
side ring containing two nitrogen atoms. It is the only amin-
obisphosphonate indicated for the treatment of skeletal com-
plications secondary to bone metastases derived from solid
tumours including hormone-refractory prostate cancer
(HRPC), breast cancer (BC), lung cancer (LC) and renal cell car-
cinoma (RCC).8,9
Patients (range 40–83 years) with bone metastases from
breast and lung cancer were enrolled in order to evaluate the
impact of the addition of bisphosphonates therapy to standard
treatments in terms of (i) pain control, (ii) quality of life (QoL)
and (iii) toxicity and to evaluate (iv) any relations between clin-
ical activity and the occurrence of SREs.9 The majority of pa-
tients treated with chemotherapy or hormonal therapy
received ZOL 4 mg every 3–4 weeks for at least 3 cycles. No sig-
nificant improvement in performance status of patients after
12 cycles of ZOL (p = 0.1672)was recorded. A statistically signif-
icant early and long-lasting amelioration of both pain, narcotic
scores and QoL was found. An inverse correlation between
bone tumour response and SREs was also found (p = 0.019).
ZOL addition induces a clinical benefit and improvesQoL of pa-
tientswith bonemetastases. Moreover, the occurrence of bone
clinical response is related to a reduced risk of SREs.10
2. Molecular mechanism of action of
zoledronic acid
Nitrogen-containing bisphosphonates such as ZOL interfere
with the mevalonate biosynthetic pathway, and affect cellular
activity and cell survival by interfering with protein prenyla-
tion and, therefore, the signalling functions of key regulatory
proteins.
ZOL binds and blocks the enzyme farnesylpyrophosphate
synthase (FPPS) in the HMG-CoA reductase pathway,11 re-
quired for the synthesis of farnesyl and geranylgeranyl lipidic
residues, and thereby suppresses prenylation of small GTPas-
es that regulate the proliferation, invasive properties and pro-
angiogenic activity of human tumour cells.12 The addition of a
lipidic residue to all the small GTP-binding proteins is essen-
tial for their correct location on the inner side of the plasma
membrane and for their consequent activation by external
signals. This phenomenon is known as prenylation, and is
important for proper sub-cellular protein trafficking (see ‘lipid
anchored protein’ for the principles of this phenomenon).13
Isoprenoids are derived from the mevalonate pathway that
starts with the conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonic acid, catalysed by the rate-limiting enzyme,
3-hydroxy-3-methylglutaryl-CoA reductase. The pathway
triggered by this reaction can lead to the synthesis of a key
isoprenoid molecule, the farnesylpyrophosphate (FPP) whose
formation is catalysed by the farnesylpyrophosphate syn-
thase (FPPS). FPP can either be converted by a series of reac-
tions in cholesterol or be transferred on target cellular
proteins as FPP itself (reaction catalysed by farnesyl-transfer-
ase), or is first converted into geranylgeranyl pyrophosphate
and then transferred to cellular proteins by type I or type II
geranylgeranyltransferase. The incorporation of lipid mole-
cules within GTPases is important for their targeted localisa-
tion and anchorage on the inner side of the cell membrane
and for consequent signal activation. Upon activation, small
GTPases play important roles in cellular processes required
for osteoclastic bone resorption including cytoskeleton actin
structure, membrane ruffling, vesicle transport and signalling
pathways that regulate apoptosis.14
Zoledronic acid are the more specific inhibitor of FPPS,
affecting the synthesis of both farnesyl and geranylgeranyl li-
pid residues.12,14
While inhibition of protein prenylation may affect many
proteins found in an osteoclast, disruption to the lipid modi-
fication of Ras, Rho, Rac proteins has been speculated to
underlie the effects of bisphosphonates. These proteins can
affect both osteoclastogenesis, cell survival and cytoskeletal
dynamics. In particular, the cytoskeleton is vital for maintain-
ing the ‘ruffled border’ that is required for contact between a
resorbing osteoclast and a bone surface.15
Recently, Monkkonen group has hypotesised and alterna-
tive NBPsmechanism of action.16 In detail, the FPPS inhibition
leads to the upstream generation and accumulation of the
ATP analogue triphosphoric acid 1-adenosin-5-yl ester 3-(3-
methylbut-3-enyl) ester (ApppI) that is able to induce in vitro
osteoclast apoptosis via the inhibition of mitochondrial
ADP/ATP translocase.16 Furthermore, the same group have
recently demonstrated the in vivo existence of ApppI in
murine peritoneal macrophages following zoledronic acid
administration.17
3. Anti-tumour activity of zoledronic acid
Anti-tumour activity of different BPs has been demonstrated
mainly in breast, prostate and myeloma cell lines. In vitro
studies have shown clear anti-tumour effects of BPs, particu-
larly zoledronic acid, as demonstrated by induction of tumour
cell apoptosis and inhibitory effects on tumour cell adhesion,
invasion, tumour cell viability and proliferation and
angiogenesis.
There are several published reports describing the in vitro
pro-apoptotic effects of BPs on osteoclasts and tumour
cells.18,19 Zoledronic acid-induced tumour cell apoptosis has
been demonstrated to be associated with the release of cyto-
chrome c and resulting activation of the caspase pathway via
the inhibition of the mevalonate pathway and the consequent
inhibition of prenylation of essential signalling G proteins
such as Ras, Rac and Rho. In support of this, the mevalonate
intermediates GGOH and FOH are able to inhibit the zoledron-
ic acid-induced suppression of protein prenylation, activation
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cell lines.
One of the primary mechanisms responsible for the direct
anti-tumour activity of bisphosphonates is induction of tu-
mour cell apoptosis. Recently we have demonstrated that
ZOL induces apoptosis and growth inhibition in human epi-
dermoid cancer cells, together with depression of Ras signal-
ling and of Erk and Akt survival pathways.19 These effects
occurred together with poly (ADP ribose) polymerase (PARP)
fragmentation and the activation of caspase-3.20 Moreover,
the latter seemed to be essential for apoptosis induced by
NBPs in this experimental model. The synthesis of isopre-
noids appeared largely responsible for the biological and bio-
chemical effects of NBPs since the addition of farnesol, which
restores farnesylation, to tumour cells completely antago-
nized apoptosis and the inhibition of Ras activity in tumour
cells exposed to NBPs.20 These data suggest that the activity
of NBPs could be due to the inactivation of the FPPS activity.20
Moreover, it was reported that ZOL induced growth inhibition
on both androgen-dependent LnCaP and androgen-indepen-
dent PC3 prostate cancer cell lines21 with G1 accumulation.
Senaratne et al. showed that the effects of ZOL in human
breast cancer cell lines (MDA-MB-231 and MCF-7) were associ-
ated with cytochrome c release from the mitochondria, in-
duced by modulating expression of Bcl-2 and subsequent
caspase-3 activation. These events might be precipitated by
inhibition of Ras activation, which requires protein farnesyla-
tion.22 ZOL has also been shown to cause tumour cell accu-
mulation in the S phase of the cell cycle.23
Recently, it has been investigated the role of caspase-2 in
the apoptosis induced by ZOL.24 In Casp2(–/–) mouse embry-
onic fibroblasts, for the absence of caspase-2, Bid and Bax
activation, and cytochrome c release are significantly delayed
following drug treatment to indicate that caspase-2 is re-
quired for apoptosis induced by cytoskeletal disruption.24
Recent research indicated for the first time a ZOL anti-
tumoural effect and apoptosis on primary tumours and vis-
ceral metastases. In human colon carcinoma HCT-116 cells
ZOL strongly inhibited the proliferation paralleled to a G1 cell
cycle accumulation and to an induction of apoptosis via a cas-
pase dependent mechanism.25
However, there is little published preclinical information
to support the clinical benefits of ZOL for renal cancer meta-
static to bone. Pandha et al. observed its marked anti-prolifer-
ative and apoptotic effects in three renal carcinoma cancer
cell lines through non-mitochondrial pathways but it was
also associated with high degrees of cellular stress, as evi-
denced by the induction of mismatch repair protein and
superoxide dismutase.26
Several in vitro studies have shown that BPs inhibit adhe-
sion of tumour cells to extracellular matrix (ECM) proteins,
thereby impairing the process of tumour cell invasion and
metastasis.27,28 Data reported by Wood et al. indicate that
inhibition of tumour cell adhesion to ECM proteins is depen-
dent on inhibition of protein prenylation. Therefore, inhibi-
tion of the mevalonate pathway and induction of caspase
activity are important for the inhibitory effects of the bis-
phosphonate compound zoledronic acid. Furthermore, it
has been shown that an activating Ras mutation enhanced
the adhesion of a normal breast epithelial cell line to ECMproteins, suggesting that increased Ras activation may in-
crease the metastatic potential of breast cancer cells.29 Thus,
by inhibiting protein prenylation and Ras signalling, ZOL
should reduce the ability of tumour cells to expand once they
colonise bone.28
In addition to direct anti-tumour mechanisms, NBPs might
modulate the immune system to target and eliminate cancer
cells. In particular, NBPs induce significant dose-dependent
expansion of cT cells both in vitro and in vivo, mainly affecting
the Vc9Vd2 subset. T-cells expressing the Vc9Vd2 T-cell recep-
tor play an important role in immune system surveillance
and defense. In fact, cdT cells showed potent MHC-unre-
stricted lytic activity against different tumour cells in vitro,
suggesting their potential utility as anti-cancer therapy.29
In vitro and in vivo studies have shown that ZOL and other
NBPs have anti-angiogenic effects.30,31 In vitro assays showed
that ZOL could inhibit the proliferation of human umbilical
vein epithelial cells induced by fetal calf serum and basic
fibroblast growth factor (bFGF) in a dose-dependent manner.
These findings have been confirmed in vivo; systemic admin-
istration of 3 lg/kg zoledronic acid to mice resulted in potent
inhibition of angiogenesis induced by subcutaneous implants
impregnated with bFGF.32 The inhibitory effect of ZOL on
endothelial cell adhesion and migration is mediated, at least
in part, by modulation of integrins that are involved in angio-
genesis.33 More recently, Bellahce`ne group34 have hypothes-
ised that ZOL alters the recruitment to focal adhesion sites
of integrins alphavbeta3 and alphavbeta5 involved in angio-
genesis. In fact, ZOL generated a significant decrease in alp-
havbeta3 and alphavbeta5 integrin expression at HUVEC cell
surface treated with zoledronate whether this mechanism
of action also applies to metastatic tumour cells is under
investigation.34
However, the role of ZOL as anti-angiogenic agent is no
certain, in fact unlike previous studies that demonstrated
the anti-angiogenic activity exerted by ZOL together with
the inhibition of tumour cell bone invasiveness by a transient
reduction of pro-angiogenic growth factors, such as VEGF,
bFGF and MMP-2 circulating levels,35 a very recent paper re-
ports that ZOL did not appear to exert an angiogenic activity
as there was no reduction of VEGF and bFGF circulating levels
after zoledronic acid infusion.364. New strategies to potentiate zoledronate
anti-tumour effects
It is important to consider the pharmacokinetic properties of
ZOL that limit its potential anti-tumour activity in vivo by not
allowing the achievement of anti-tumour concentrations at
extra-skeletal sites. There is a rapid elimination from plasma
resulting from renal excretion and rapid uptake and accumu-
lation within bone.37 At 4mg intravenous dose of ZOL admin-
istrated over 15min results in a sharp increase in its
concentration, as shown by estimated distribution and
elimination of the drug which results in a peak plasma con-
centration of ZOL (Cmax) of approximatevely 1M. The rapid
decline in plasma concentrations, falling to <1% of Cmax by
24 h post-dose, is followed by prolonged very low drug
plasma concentrations (terminal elimination half-life, t1/2c,
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file.37–39 Therefore, because of the most important limits of
ZOL, its pharmacokinetic profile, further efforts are required
in order to allow the clinical translation of experimental re-
sults recorded to date and to increase the anti-cancer activity
of these drugs.
4.1. Combination with other drugs
Evidence from in vitro and in vivo models indicates that ZOL
synergises with a variety of anti-cancer agents including che-
motherapeutic drugs, molecular targeted agents, and other
biological agents.
Based on their ability to inhibit crucial processes of protein
isoprenylation ZOL and other NBPs have been combined with
different biological agents. In fact, the prenyltransferases are
not strictly specific, and a small G protein can be the substrate
for different enzymes.
We have recently used the farnesyltransferase inhibitor
(FTI) R115777 together with ZOL, and evaluated the effects of
the combinatory treatment on growth inhibition and apopto-
sis of epidermoid cancer cells. ZOL and FTI given in combina-
tion were strongly synergistic since a CI50 (the combination
index of the two drugs calculated for 50% cell survival by
isobologram analysis) less than 0.5 was recorded with the
dedicated software Calcusyn. Notably, low concentrations of
FTI induced a strong increase of Ras expression with only a
moderate reduction of Ras activity that was, on the other
hand, significantly reduced by the combined treatment.20
Moreover, ZOL/FTI combination allowed the compounds to
be active in terms of tumour cell growth inhibition at in vivo
achievable therapeutic concentrations (0.1 lM range for both
drugs).20 These data suggest that escape mechanisms for
the inhibition of isoprenylation of Ras might be based on
the geranylgeranylation or other prenylating processes.38
The addition of farnesol to cells treated with the combination
abolished the effects of the BPs/FTI combination on apoptosis
and on the activity of the signalling molecules. These data
suggest that the synergistic growth-inhibitory and pro-apop-
totic effects produced by the NBP/FTI combination involve
the inhibition of both Erk and Akt survival pathways acting
in these cells in a Ras-dependent fashion.20
A synergistic interaction between R115777 and ZOL was
also found on both androgen-independent PC3 and andro-
gen-dependent LNCaP prostate cancer cell lines.40 These ef-
fects were paralleled by disruption of Ras! Erk and Akt
survival pathways, consequently decreased phosphorylation
of both mitochondrial bcl-2 and bad proteins, and caspase
activation. Moreover, ZOL/R115777 combination induced
cooperative effects also in vivo on tumour growth inhibition
of prostate cancer xenografts in nude mice with a significant
survival increase.41 These effects were paralleled by en-
hanced apoptosis and inactivation of both Erk and Akt. In
conclusions, the combination between ZOL and FTI leads to
enhanced anti-tumour activity in human prostate adenocar-
cinoma cells likely through a more efficacious inhibition of
Ras-dependent survival pathways and consequent bcl-related
proteins-dependent apoptosis.42
NBPs and chemotherapy have increasingly gained favour
in the treatment of metastatic hormone resistant prostateand breast cancer. Evidence of synergistic anti-tumour effects
of ZOL in combination with other agents in preclinical breast
cancer studies was recently reviewed by Winter et al.42
Recent evidence in multiple animal models and in clinical
studies has supported the biologic relevance of the anti-
tumour effects of ZOL. In nude mice bearing LuCaP tumours,
ZOL enhanced the cytotoxic effect of docetaxel (DTX) inhibit-
ing significantly the growth of tumour cells in the bone. Ullen
et al.43 reported results from morphologic analyses demon-
strating that the anti-tumour effects were mainly attributed
to the inhibition of proliferation.
We have preliminary results about sequence-dependent
synergistic effects of ZOL and docetaxel combination on
growth inhibition and apoptosis of human prostate cancer
cells. We have found a synergistic growth inhibition when
DTX was administered 24 h before ZOL. On the basis of these
results, we have designed a phase I clinical study on the com-
bination between these two drugs metronomically adminis-
tered in two different sequences in hormone-refractory
advanced prostate cancer patients. The aim of this study
was to perform a pharmacodynamic evaluation of the effects
of the two sequential combinations through the dosage of
serum angiogenic, immunologic and bone factors, and
through the study of both lymphocyte sub-populations and
modification of isoprenylation of intracellular proteins. Final
end-point of the study was the evaluation of information
for further clinical development of this combination, such
as toxicity, as well as information about the mechanism of ac-
tion of the combination to be translated in the preclinical set-
ting. We have completed the first level without significant
toxicities, and we have enrolled the first three patients of
the second level. In the first level, we have completed the 12
cycles in only one patient, and 42 cycles were globally admin-
istered. The serum level changes of biological markers were
determined before, during and after the pharmacological
treatment. Interestingly, in the patient who completed the
12 cycles of therapy a significant reduction of both interleu-
kin-8 (a pro-angiogenic factor) and -6 (a prostate cancer
growth factor) was recorded. Similar results were obtained
in another patient with SD. These findings were also paral-
leled by a significant reduction of PSA. We are now complet-
ing the evaluation of a panel of circulating angiogenic
factors (interleukin-8 and -12, VEGF, PDGF), cytokines (TNF al-
pha, IFN gamma, GM-CSF, RANTES, interleukin-1, -2, -6 and -
4) and chromogranin A. We have also collected peripheral
blood mononuclear cells on which we will investigate T lym-
phocyte subpopulation distribution and the isoprenylation of
the chaperone protein HDJ2. On the basis of the results of this
study, we will design a phase III clinical study based on the 2
sequences of administration.
Moreover, in a pilot study to assess the safety and efficacy
of DTX and ZOL in patients with metastatic hormone-refrac-
tory prostate cancer, the combination therapy decreased ser-
um prostate-specific antigen levels by >50%, and resulted in a
concurrent improvement in symptoms.44
In a phase II trial of estramustine, ZOL, and DTX in pa-
tients with metastatic androgen-independent prostate cancer
patients had prostate-specific antigen decreases of >50% for a
duration of 5–63 weeks and a clinically notable reduction in
pain, suggesting that this combination therapy can delay dis-
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the potential synergistic effects that docetaxel and zoledronic
acid may have on cancer cells in the bone microenvironment
are necessary. Finally, a new orally available mTOR inhibitor
RAD001 (Everolimus) inhibits growth of prostate cancer in
the bone, and the inhibitory effects are increased by combina-
tion with DTX and ZOL. Moreover, RAD001 had a significant
impact on maintenance of body weight. RAD001 may hold
promise for its effects on both metastatic CaP and the impor-
tant syndrome of tumour cachexia.46
The findings of synergy of interaction between ZOL and
other agents could reduce the ZOL concentrations required
for anti-tumour activity, and could allow the achievement of
effective in vivo levels.
4.2. New molecular targets
New technological platforms are required to drive molecular
research and to identify suitable targets of BPs action and
understand cell consequences of the inhibition of the targetZOL
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pounds. Moreover, protein microarrays might allow discovery
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related to the clinical response to bisphosphonate-based ther-
apy. Identification of critical interactions within the proteome
network is a potential starting point for drug development,
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preliminary results47 about the gene modulation induced by
ZOL in androgen-resistant prostate cancer PC3 cell line ana-
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proteins encoded by the modulated genes was evaluated
through western blotting analysis using specific antibodies.
We found that the upregulated and downregulated genes
were 73/33.000 (four genes were downregulated and 69 genes
were upregulated). Among the upregulated genes, the genes
coding for calreticulin gene, n-myc downstream regulated
gene 1 (NDGR1) and catenin gene resulted highly upregulated
with a fold-change of 11.47, 4.81 and 3.25, respectively.
Among the downregulated genes, the gene coding for cys-
teine-rich, angiogenic inducer, 61 (Cyr61) resulted highly
downregulated with a fold-change of 5.58. Cyr61 over-expres-
sion in tumour cells promotes tumour growth and vasculari-
sation. The evaluation of the involvement of these molecules
involved in angiogenesis and in differentiation of human
prostate cancer cells treated with ZOL is ongoing (Fig. 1). Pre-
liminarily, we have found the reduction of the transcriptional
activity of Cyr61 promoter in ZOL-treated PC3 cells in a time-
dependent manner (with a peak at 12 h). Moreover, Cyr61 pro-
tein expression was significantly decreased after exposure to
ZOL. Interestingly, other inhibitors of Ras (such as R115777) or
of the tyr kinase associated to EGF-R (gefitinib) or of C-Raf
(BAY 43-9006) used at equitoxic concentrations did not induce
or induced less effects on Cyr61 modulation when compared
to ZOL. Moreover, ZOL downregulated Cyr61 and blocked the
Ras-raf-1-dependent pathway. The effects of ZOL were antag-
onised by the addition of either farnesol or geranylgeraniol.
Thereafter, we have investigated on the role of Cyr61 in apop-
tosis and growth regulation of PC3 cells using a shRNA for
Cyr61 in order to downregulate the expression of the protein.
shCYR61 enhanced growth inhibition induced by ZOL with a
potentiation factor of 5, while the transfection of PC3 cells
with shCYR61 alone is ineffective. The sensitisation of PC3
cells to the anti-proliferative effects of ZOL induced by
CYR61 knock-down is paralleled by the inactivation of Ras,
Erk and Akt. Since Cyr61 is a ligand of alphavbeta3 integrin,
we have evaluated the effects of Cyr61 knock-down on motil-
ity and invasion. We have found that shCyr61 transfection in-
duced 45% and 20% reduction of motility and invasion,
respectively, but treatment of shCyr61-transfected cells with
ZOL induced 75% and 30% inhibition of motility and invasion,
respectively. Moreover, Cyr61 down-modulation induced by
ZOL sensitises prostate cancer cells to DTX. In fact, the treat-
ment of PC3 with DTX induced an about 2-fold increase of
Cyr61. In conclusion, Cyr61 downregulation is involved in
the regulation of motility processes and, indirectly, of cell
growth inhibition induced by ZOL46. We are now evaluating
the activity of blocking anti-CYR61 antibodies in inducing
the potentiation of ZOL anti-proliferative effects (Fig. 1).
These results could be useful in designing new therapeutical
approaches in androgen-independent prostate cancer.
5. Conclusions
Based on these potential anti-cancer properties, several clini-
cal trials have been initiated to test the combination of ZOL
and other agents. The accumulated encouraging evidence
indicates that ZOL is an attractive anti-cancer agent that
promises to be an unexpected next exciting therapy for pa-
tients with bone tumours and metastases.Conflict of interest statement
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